{"id":384667,"date":"2020-11-19T02:50:02","date_gmt":"2020-11-19T07:50:02","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384667"},"modified":"2020-11-19T02:50:02","modified_gmt":"2020-11-19T07:50:02","slug":"oncopeptides-interim-report-q3-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/","title":{"rendered":"Oncopeptides: INTERIM REPORT Q3 2020"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">STOCKHOLM<\/span>, <span class=\"xn-chron\">Nov. 19, 2020<\/span> \/PRNewswire\/ &#8212;<\/p>\n<p>\n        <b>Summary<\/b>\n      <\/p>\n<p \/>\n<p>\n        <b>Financial overview <span class=\"xn-chron\">July 1 &#8211; September 30, 2020<\/span><\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Net sales amounted to <span class=\"xn-money\">SEK 0.0 M<\/span> (0.0)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>Loss for the period was <span class=\"xn-money\">SEK 383.4 M<\/span> (loss: 189.8)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>Loss per share, before and after dilution, was <span class=\"xn-money\">SEK 5.71<\/span> (loss: 3.53)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>On <span class=\"xn-chron\">September 30<\/span> cash and cash equivalents amounted to <span class=\"xn-money\">SEK 1,251.6 M<\/span> (1,122.3)<\/li>\n<\/ul>\n<p>\n        <b>Significant events during the period <span class=\"xn-chron\">July 1 &#8211; September 30, 2020<\/span><\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>The FDA granted priority review of melflufen for patients with triple-class refractory multiple myeloma and set the PDUFA date to <span class=\"xn-chron\">February 28, 2021<\/span><\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>Patient enrolment in the pivotal phase 3 OCEAN study was completed including 495 patients<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>Patient enrolment for the phase 1\/2 study in AL-amyloidosis began, this is the first study with melflufen in an indication outside multiple myeloma<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>The phase 2 PORT study evaluating alternative administration of melflufen and dexamethasone in multiple myeloma started<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>Oncopeptides further coordinated the global and US organizational structure and appointed <span class=\"xn-person\">Mohamed Ladha<\/span> as General Manager of the US Business Unit<\/li>\n<\/ul>\n<p>\n        <b>Significant events after the reporting period<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Oncopeptides announced that the company intends to submit a conditional marketing authorization application for melflufen in the EU<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>Oncopeptides entered into a \u20ac40 M loan agreement with the European Investment Bank (EIB)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>An IND application was submitted to the FDA to initiate clinical studies with OPD5, Oncopeptides&#8217; second drug candidate<\/li>\n<\/ul>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"1\" class=\"prntblns\">\n<tr>\n<td class=\"prnsbts prnrbrs prnvab prnsbbs prnpl6 prnsbls prnpr6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>SEK thousand<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b><br \/>\n                    <b><br \/>\n                      <span class=\"prnews_span\"><br \/>\n                        <b>2020<br \/><\/b><br \/>\n                      <\/span>Jul &#8211; Sep<\/b><br \/>\n                  <\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b><br \/>\n                    <b><br \/>\n                      <span class=\"prnews_span\"><br \/>\n                        <b>2019<br \/><\/b><br \/>\n                      <\/span>Jul &#8211; Sep<\/b><br \/>\n                  <\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b><br \/>\n                    <b><br \/>\n                      <span class=\"prnews_span\"><br \/>\n                        <b>2020 <br \/><\/b><br \/>\n                      <\/span>Jan &#8211; Sep<\/b><br \/>\n                  <\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\">\n<p class=\"prnews_p\" \/>\n              <b><br \/>\n                <b><br \/>\n                  <span class=\"prnews_span\"><br \/>\n                    <b>2019<\/b><br \/>\n                  <\/span><br \/>\n                  <br \/>Jan &#8211; Sep<\/b><br \/>\n              <\/b>\n            <\/td>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>2019<\/b><br \/>\n                  <b><br \/>\n                    <b>\u00a0 <br \/>Jan &#8211; Dec<\/b><br \/>\n                  <\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Net sales<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Operating loss<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-383,498<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-189,597<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-1,079,706<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-495,148<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-739,392<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Loss before tax<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-383,784<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-189,710<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-1,080,653<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-495,520<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-739,920<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Loss for the period<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-383,357<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-189,780<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-1,081,727<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-495,801<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-740,705<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Earnings per share before and after dilution (SEK)<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-5.71<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-3.53<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-17.87<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-9.90<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-14.33<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Cash flow from operating activities<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-340,841<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-207,774<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-939,347<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-473,592<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-690,566<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Cash and cash equivalents at the end of the period<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,251,629<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,122,297<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,251,629<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,122,297<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">926,186<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Research &amp; development costs\/operating expenses %<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">50%<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">80%<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">59%<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">79%<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">74%<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\n        <b>Conference call for investors, analysts and the media<\/b>\n      <\/p>\n<p>The Interim Report Q3 2020 and an operational update will be presented by CEO Marty J Duvall and members of Oncopeptides Leadership team, <span class=\"xn-chron\">Thursday November 19, 2020<\/span> at 14:00 (CET). <\/p>\n<p>The conference call will also be streamed via a link on the website: www. oncopeptides.com.<\/p>\n<p>Phone numbers for participants from:<\/p>\n<p>\n        <span class=\"xn-location\">Sweden<\/span>: +46 8 566 426 92 <br \/><span class=\"xn-location\">Europe<\/span>: +44 3333 009 274 <br \/><span class=\"xn-location\">USA<\/span>: +1 833 526 83 47<\/p>\n<p>Financial calendar<\/p>\n<p>Year-end Report 2020: <span class=\"xn-chron\">February 18, 2021<\/span><\/p>\n<p>Annual Report 2020: Week starting with <span class=\"xn-chron\">April 26, 2021<\/span><\/p>\n<p>Interim Report Q1 2021: <span class=\"xn-chron\">May 26, 2021<\/span><\/p>\n<p>Annual General Meeting 2021: <span class=\"xn-chron\">May 26, 2021<\/span><\/p>\n<p>For more information<\/p>\n<p>Marty J Duvall, CEO, Oncopeptides <br \/>E-mail:\u00a0<a target=\"_blank\" href=\"mailto:marty.duvall@oncopeptides.com\" rel=\"nofollow noopener noreferrer\">marty.duvall@oncopeptides.com<\/a><\/p>\n<p>Rein Piir, Head of Investor Relations, Oncopeptides <br \/>E-mail:\u00a0<a target=\"_blank\" href=\"mailto:rein.piir@oncopeptides.com\" rel=\"nofollow noopener noreferrer\">rein.piir@oncopeptides.com<\/a>\u00a0\u00a0\u00a0 <br \/>Cell phone: +46 70 853 72 92<\/p>\n<p>This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at <span class=\"xn-chron\">08:00 CET<\/span> on <span class=\"xn-chron\">November 19, 2020<\/span>.<\/p>\n<p>\n        <b>About Oncopeptides<\/b>\n      <\/p>\n<p>Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is in development as a new treatment for the hematological malignancy multiple myeloma and is being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study.\u00a0Based on the results from the HORIZON study a New Drug Application has been submitted to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with triple-class refractory multiple myeloma. The FDA,\u00a0has\u00a0granted the\u00a0New Drug Application a priority review, with a PDUFA date of <span class=\"xn-chron\">February 28<\/span>, 2021.Oncopeptides&#8217; global Headquarters is in <span class=\"xn-location\">Stockholm, Sweden<\/span> and the U.S. Headquarters is situated in <span class=\"xn-location\">Boston, Mass.<\/span> The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2987746-1&amp;h=2360350491&amp;u=http%3A%2F%2Fwww.oncopeptides.com%2F&amp;a=www.oncopeptides.com\" rel=\"nofollow noopener noreferrer\">www.oncopeptides.com<\/a>.<\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2987746-1&amp;h=3860056411&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2987746-1&amp;h=3985946647&amp;u=https%3A%2F%2Fnews.cision.com%2Foncopeptides-ab%2Fr%2Finterim-report-q3-2020%2Cc3239894&amp;a=https%3A%2F%2Fnews.cision.com%2Foncopeptides-ab%2Fr%2Finterim-report-q3-2020%2Cc3239894\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/oncopeptides-ab\/r\/interim-report-q3-2020,c3239894<\/a>\n      <\/p>\n<p>The following files are available for download:<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt1 prnsbr1 prnsbb1 prnsbl1\">\n<tr>\n<td class=\"prngen9\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2987746-1&amp;h=2271773359&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F3239894%2F1337103.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F3239894%2F1337103.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Main\/15404\/3239894\/1337103.pdf<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen9\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">The full report (PDF)<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen9\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2987746-1&amp;h=3768597665&amp;u=https%3A%2F%2Fmb.cision.com%2FPublic%2F15404%2F3239894%2F97155f9e649c818b.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FPublic%2F15404%2F3239894%2F97155f9e649c818b.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Public\/15404\/3239894\/97155f9e649c818b.pdf<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen9\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Press release (PDF)<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97843&amp;sd=2020-11-19\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/oncopeptides-interim-report-q3-2020-301176786.html\">http:\/\/www.prnewswire.com\/news-releases\/oncopeptides-interim-report-q3-2020-301176786.html<\/a><\/p>\n<p>SOURCE  Oncopeptides AB<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO97843&amp;Transmission_Id=202011190246PR_NEWS_USPR_____IO97843&amp;DateId=20201119\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire STOCKHOLM, Nov. 19, 2020 \/PRNewswire\/ &#8212; Summary Financial overview July 1 &#8211; September 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 383.4 M (loss: 189.8) Loss per share, before and after dilution, was SEK 5.71 (loss: 3.53) On September 30 cash and cash equivalents amounted to SEK 1,251.6 M (1,122.3) Significant events during the period July 1 &#8211; September 30, 2020 The FDA granted priority review of melflufen for patients with triple-class refractory multiple myeloma and set the PDUFA date to February 28, 2021 Patient enrolment in the pivotal phase 3 OCEAN study was completed including 495 patients Patient enrolment for the phase 1\/2 study in AL-amyloidosis began, this is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncopeptides: INTERIM REPORT Q3 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384667","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncopeptides: INTERIM REPORT Q3 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncopeptides: INTERIM REPORT Q3 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire STOCKHOLM, Nov. 19, 2020 \/PRNewswire\/ &#8212; Summary Financial overview July 1 &#8211; September 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 383.4 M (loss: 189.8) Loss per share, before and after dilution, was SEK 5.71 (loss: 3.53) On September 30 cash and cash equivalents amounted to SEK 1,251.6 M (1,122.3) Significant events during the period July 1 &#8211; September 30, 2020 The FDA granted priority review of melflufen for patients with triple-class refractory multiple myeloma and set the PDUFA date to February 28, 2021 Patient enrolment in the pivotal phase 3 OCEAN study was completed including 495 patients Patient enrolment for the phase 1\/2 study in AL-amyloidosis began, this is &hellip; Continue reading &quot;Oncopeptides: INTERIM REPORT Q3 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T07:50:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97843&amp;sd=2020-11-19\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-interim-report-q3-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-interim-report-q3-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncopeptides: INTERIM REPORT Q3 2020\",\"datePublished\":\"2020-11-19T07:50:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-interim-report-q3-2020\\\/\"},\"wordCount\":680,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-interim-report-q3-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO97843&amp;sd=2020-11-19\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-interim-report-q3-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-interim-report-q3-2020\\\/\",\"name\":\"Oncopeptides: INTERIM REPORT Q3 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-interim-report-q3-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-interim-report-q3-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO97843&amp;sd=2020-11-19\",\"datePublished\":\"2020-11-19T07:50:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-interim-report-q3-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-interim-report-q3-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-interim-report-q3-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO97843&amp;sd=2020-11-19\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO97843&amp;sd=2020-11-19\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-interim-report-q3-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncopeptides: INTERIM REPORT Q3 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncopeptides: INTERIM REPORT Q3 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/","og_locale":"en_US","og_type":"article","og_title":"Oncopeptides: INTERIM REPORT Q3 2020 - Market Newsdesk","og_description":"PR Newswire STOCKHOLM, Nov. 19, 2020 \/PRNewswire\/ &#8212; Summary Financial overview July 1 &#8211; September 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 383.4 M (loss: 189.8) Loss per share, before and after dilution, was SEK 5.71 (loss: 3.53) On September 30 cash and cash equivalents amounted to SEK 1,251.6 M (1,122.3) Significant events during the period July 1 &#8211; September 30, 2020 The FDA granted priority review of melflufen for patients with triple-class refractory multiple myeloma and set the PDUFA date to February 28, 2021 Patient enrolment in the pivotal phase 3 OCEAN study was completed including 495 patients Patient enrolment for the phase 1\/2 study in AL-amyloidosis began, this is &hellip; Continue reading \"Oncopeptides: INTERIM REPORT Q3 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T07:50:02+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97843&amp;sd=2020-11-19","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncopeptides: INTERIM REPORT Q3 2020","datePublished":"2020-11-19T07:50:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/"},"wordCount":680,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97843&amp;sd=2020-11-19","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/","name":"Oncopeptides: INTERIM REPORT Q3 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97843&amp;sd=2020-11-19","datePublished":"2020-11-19T07:50:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97843&amp;sd=2020-11-19","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97843&amp;sd=2020-11-19"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-interim-report-q3-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncopeptides: INTERIM REPORT Q3 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384667"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384667\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}